{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:04:34Z","timestamp":1792598674180,"version":"4.5.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,13]],"date-time":"2027-02-13T00:00:00Z","timestamp":1802476800000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA248064"],"award-info":[{"award-number":["R01 CA248064"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jmb.2025.169401","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:30:22Z","timestamp":1755822622000},"page":"169401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and Future"],"prefix":"10.1016","volume":"438","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2787-7297","authenticated-orcid":false,"given":"Annapoorna","family":"Venkatachalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-7145","authenticated-orcid":false,"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2025.169401_b0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA Topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jmb.2025.169401_b0010","series-title":"Cancer Chemotherapy and Biotherapy: Principles and Practice","first-page":"342","article-title":"Topoisomerase I-targeting drugs","author":"Sparreboom","year":"2011"},{"key":"10.1016\/j.jmb.2025.169401_b0015","first-page":"1535","article-title":"In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia","volume":"62","author":"Johnson","year":"1978","journal-title":"Cancer Treatm. Rep."},{"key":"10.1016\/j.jmb.2025.169401_b0020","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.12688\/f1000research.20201.1","article-title":"Topoisomerases and cancer chemotherapy: recent advances and unanswered questions","volume":"8","author":"Bjornsti","year":"2019","journal-title":"F1000 Rev."},{"key":"10.1016\/j.jmb.2025.169401_b0025","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2024.103751","article-title":"From the TOP: formation, recognition and resolution of topoisomerase DNA protein crosslinks","volume":"142","author":"Wojtaszek","year":"2024","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.jmb.2025.169401_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-017-3334-5","article-title":"DNA topoisomerase-targeting chemotherapeutics: what's new?","volume":"80","author":"Cuya","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jmb.2025.169401_b0045","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1073\/pnas.74.9.3800","article-title":"Strand breakage by the DNA untwisting enzyme results in covalent attachment of the enzyme to DNA","volume":"74","author":"Champoux","year":"1977","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169401_b0050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1073\/pnas.69.1.143","article-title":"An activity from mammalian cells that untwists superhelical DNA\u2013a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay)","volume":"69","author":"Champoux","year":"1972","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169401_b0055","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1002\/j.1460-2075.1990.tb07908.x","article-title":"Eukaryotic topoisomerases recognize nuclei acid topology by preferentially interacting with DNA crossovers","volume":"9","author":"Zechiedrich","year":"1990","journal-title":"EMBO J."},{"key":"10.1016\/j.jmb.2025.169401_b0060","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1073\/pnas.81.22.6958","article-title":"Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome","volume":"81","author":"Fleischmann","year":"1984","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169401_b0065","first-page":"141","article-title":"Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin","volume":"7","author":"Gilmour","year":"1987","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0092-8674(88)90203-6","article-title":"Transcription-dependent DNA supercoiling in yeast DNA topoisomerase mutants","volume":"54","author":"Brill","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0075","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0092-8674(88)90140-7","article-title":"Supercoiling of intracellular DNA can occur in eukaryotic cells","volume":"55","author":"Giaever","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12551-016-0215-9","article-title":"DNA supercoiling during transcription","volume":"8","author":"Ma","year":"2016","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.jmb.2025.169401_b0085","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/j.1460-2075.1985.tb03766.x","article-title":"Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA","volume":"4","author":"Muller","year":"1985","journal-title":"EMBO J."},{"key":"10.1016\/j.jmb.2025.169401_b0090","first-page":"1674","article-title":"RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I","volume":"56","author":"Buckwalter","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0095","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/ncb1984","article-title":"Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription","volume":"11","author":"Tuduri","year":"2009","journal-title":"Nature Cell Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0100","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.molcel.2014.10.020","article-title":"Transcription-coupled nucleotide excision repair factors promote R-loop-induced genome instability","volume":"56","author":"Sollier","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0105","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1126\/science.1205016","article-title":"Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I","volume":"332","author":"Kim","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169401_b0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.dnarep.2017.06.005","article-title":"The Top1 paradox: friend and foe of the eukaryotic genome","volume":"56","author":"Kim","year":"2017","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.jmb.2025.169401_b0115","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant antitumor agents. I. The isolation and structure of camptothecin a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata","volume":"88","author":"Wall","year":"1966","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jmb.2025.169401_b0120","doi-asserted-by":"crossref","first-page":"14873","DOI":"10.1016\/S0021-9258(17)38654-4","article-title":"Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I","volume":"260","author":"Hsiang","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0125","first-page":"1722","article-title":"Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin","volume":"48","author":"Hsiang","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0130","first-page":"2643","article-title":"Action of camptothecin on mammalian cells in culture","volume":"32","author":"Li","year":"1972","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0135","first-page":"6919","article-title":"Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons","volume":"50","author":"D'Arpa","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0140","first-page":"6318","article-title":"Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin","volume":"49","author":"Bjornsti","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0145","first-page":"6577","article-title":"Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations","volume":"60","author":"Urasaki","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0150","doi-asserted-by":"crossref","first-page":"25463","DOI":"10.1016\/S0021-9258(19)74414-7","article-title":"Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance","volume":"268","author":"Tanizawa","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0155","first-page":"6404","article-title":"Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I","volume":"48","author":"Gupta","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0160","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1021\/cr900097c","article-title":"DNA Topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition","volume":"109","author":"Pommier","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jmb.2025.169401_b0165","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.1073\/pnas.242259599","article-title":"The mechanism of topoisomerase I poisoning by a camptothecin analog","volume":"99","author":"Staker","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169401_b0170","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/jnci\/86.11.836","article-title":"Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials","volume":"86","author":"Tanizawa","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jmb.2025.169401_b0175","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nsmb.2501","article-title":"Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition","volume":"20","author":"Berti","year":"2013","journal-title":"Nature Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1083\/jcb.201406099","article-title":"Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells","volume":"208","author":"Zellweger","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0185","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0190","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1074\/jbc.M106287200","article-title":"S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function","volume":"277","author":"Cliby","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0195","doi-asserted-by":"crossref","first-page":"20303","DOI":"10.1074\/jbc.M300198200","article-title":"Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes","volume":"278","author":"Furuta","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0200","doi-asserted-by":"crossref","first-page":"18641","DOI":"10.1074\/jbc.M313536200","article-title":"Rad9 protects cells from topoisomerase poison-induced cell death","volume":"279","author":"Loegering","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0205","first-page":"3026","article-title":"Camptothecin, a specific inhibitor of type I DNA topoisomerase, induced DNA breakage at replication forks","volume":"8","author":"Avemann","year":"1988","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0210","first-page":"4221","article-title":"Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication","volume":"6","author":"Snapka","year":"1986","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0215","doi-asserted-by":"crossref","first-page":"24159","DOI":"10.1074\/jbc.272.39.24159","article-title":"Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin","volume":"272","author":"Desai","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0220","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1006\/excr.2002.5550","article-title":"The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies","volume":"277","author":"Rasheed","year":"2002","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jmb.2025.169401_b0225","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1128\/MCB.23.7.2341-2350.2003","article-title":"Transcription-dependent degradation of topoisomerase I-DNA covalent complexes","volume":"23","author":"Desai","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0230","doi-asserted-by":"crossref","first-page":"21074","DOI":"10.1074\/jbc.M803493200","article-title":"A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes","volume":"283","author":"Lin","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0235","doi-asserted-by":"crossref","first-page":"28084","DOI":"10.1074\/jbc.M109.030601","article-title":"Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks","volume":"284","author":"Lin","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0240","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1038\/s41467-021-25252-9","article-title":"PARylation prevents the proteasomal degradation of topoisomerase I DNA-protein crosslinks and induces their deubiquitylation","volume":"12","author":"Sun","year":"2021","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169401_b0245","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1016\/j.molcel.2023.07.004","article-title":"FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways","volume":"83","author":"Huang","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0250","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/nar\/30.5.1198","article-title":"Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase","volume":"30","author":"Debethune","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169401_b0255","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-biochem-032620-105820","article-title":"DNA-protein crosslinks and their resolution","volume":"91","author":"Weickert","year":"2022","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jmb.2025.169401_b0260","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.279.5356.1504","article-title":"Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA","volume":"279","author":"Redinbo","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169401_b0265","doi-asserted-by":"crossref","first-page":"36518","DOI":"10.1074\/jbc.M508898200","article-title":"Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages","volume":"280","author":"Interthal","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0270","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1042\/BJ20101841","article-title":"Effects of DNA and protein size on substrate cleavage by human tyrosyl-DNA phosphodiesterase 1","volume":"436","author":"Interthal","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.jmb.2025.169401_b0275","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1093\/nar\/gkw109","article-title":"Immunodetection of human topoisomerase I-DNA covalent complexes","volume":"44","author":"Patel","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169401_b0280","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1093\/nar\/gkx107","article-title":"Spartan deficiency causes accumulation of topoisomerase 1 cleavage complexes and tumorigenesis","volume":"45","author":"Maskey","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169401_b0285","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s41467-020-15170-7","article-title":"FAM111A protects replication forks from protein obstacles via its trypsin-like domain","volume":"11","author":"Kojima","year":"2020","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169401_b0290","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrm.2017.56","article-title":"Mechanisms of DNA-protein crosslink repair","volume":"18","author":"Stingele","year":"2017","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0295","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.230113","article-title":"Tyrosyl-DNA phosphodiesterase 1 (TDP1) and SPRTN protease repair histone 3 and topoisomerase 1 DNA-protein crosslinks in vivo","volume":"13","author":"Anticevic","year":"2023","journal-title":"Open Biol."},{"key":"10.1016\/j.jmb.2025.169401_b0300","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1074\/jbc.273.14.8425","article-title":"Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces Cerevisiae DNA topoisomerase I","volume":"273","author":"Hann","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0305","first-page":"6039","article-title":"Camptothecin overcomes mdrl-mediated resistance in human KB carcinoma cells","volume":"51","author":"Chen","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0310","first-page":"2268","article-title":"Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue","volume":"52","author":"Hendricks","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0315","first-page":"4237","article-title":"The mouse Bcrp1\/Mxr\/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin","volume":"59","author":"Allen","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0320","first-page":"4559","article-title":"Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line","volume":"59","author":"Maliepaard","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0325","first-page":"6365","article-title":"Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells","volume":"49","author":"Holm","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0330","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1038\/s41467-022-31801-7","article-title":"TDP1-independent pathways in the process and repair of TOP1-induced DNA damage","volume":"13","author":"Zhang","year":"2022","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169401_b0335","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169401_b0340","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41416-020-01199-4","article-title":"SLFN11 informs on standard of care and novel treatments in a wide range of cancer models","volume":"124","author":"Winkler","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0345","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1126\/science.adh7950","article-title":"DNA damage induces p53-independent apoptosis through ribosome stalling","volume":"384","author":"Boon","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169401_b0350","first-page":"95","article-title":"Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer","volume":"56","author":"Moertel","year":"1972","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.jmb.2025.169401_b0355","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/jm00105a017","article-title":"Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity","volume":"34","author":"Kingsbury","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0360","first-page":"4187","article-title":"Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11","volume":"51","author":"Kawato","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0365","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.jmb.2025.169401_b0370","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0375","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.molcel.2015.04.016","article-title":"Chromatin to clinic: the molecular rationale for PARP1 inhibitor function","volume":"58","author":"Feng","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0380","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/0008-5472.CAN-21-1756","article-title":"DNA-PKcs: a targetable protumorigenic protein kinase","volume":"82","author":"Dylgjeri","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0385","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1158\/1078-0432.CCR-24-3571","article-title":"Myt1 kinase: an emerging cell-cycle regulator for cancer therapeutics","volume":"31","author":"Lang","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0390","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.jmb.2025.169401_b0395","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0400","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR Inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0405","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Josse","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0410","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0415","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0420","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.2741\/2909","article-title":"The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases","volume":"13","author":"Hassa","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.jmb.2025.169401_b0425","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/bjc.1998.670","article-title":"Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064","volume":"78","author":"Bowman","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0430","first-page":"2711","article-title":"Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies","volume":"9","author":"Calabrese","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0435","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1074\/jbc.M111.296475","article-title":"Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase inhibitors reflects poisoning of both enzymes","volume":"287","author":"Patel","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0440","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/1078-0432.CCR-17-1590","article-title":"A phase I clinical trial of the poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors","volume":"24","author":"Wahner Hendrickson","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0445","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/0008-5472.CAN-11-1227","article-title":"Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas","volume":"71","author":"Kummar","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0450","doi-asserted-by":"crossref","first-page":"17572","DOI":"10.1021\/acs.jmedchem.1c01491","article-title":"Design and synthesis of indenoisoquinolines targeting topoisomerase I and other biological macromolecules for cancer chemotherapy","volume":"64","author":"Cushman","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0455","first-page":"5938","article-title":"Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells","volume":"59","author":"Brangi","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0460","first-page":"739","article-title":"The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux","volume":"61","author":"Erlichman","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0465","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1535-7163.MCT-08-0706","article-title":"The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives","volume":"8","author":"Pommier","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jmb.2025.169401_b0470","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1158\/1078-0432.CCR-18-1498","article-title":"NCI comparative oncology program testing of non-camptothecin indenoisoquinoline topoisomerase I inhibitors in naturally occurring canine lymphoma","volume":"24","author":"Burton","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0475","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00280-016-2998-6","article-title":"Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors","volume":"78","author":"Kummar","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jmb.2025.169401_b0480","article-title":"Combined inhibition of topoisomerase I and poly(ADP-ribose) polymerase: a synergistic therapeutic strategy for glioblastoma with phosphatase and tensin homolog deficiency","volume":"5","author":"Kim","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.jmb.2025.169401_b0485","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1021\/acs.jmedchem.6b01870","article-title":"Design and synthesis of chlorinated and fluorinated 7-azaindenoisoquinolines as potent cytotoxic anticancer agents that inhibit topoisomerase I","volume":"60","author":"Elsayed","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0490","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0495","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169401_b0500","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169401_b0505","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169401_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Martin","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jmb.2025.169401_b0515","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169401_b0520","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169401_b0525","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0530","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0535","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0540","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11523-024-01036-1","article-title":"Sacituzumab Govitecan: a review in unresectable or metastatic HR+\/HER2- breast cancer","volume":"19","author":"Kang","year":"2024","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0545","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting trop-2, sacituzumab govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0550","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.21037\/atm-21-1103","article-title":"Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?","volume":"9","author":"Santi","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jmb.2025.169401_b0555","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jmb.2025.169401_b0560","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jmb.2025.169401_b0565","first-page":"22","article-title":"Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer","volume":"7","author":"Saleh","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.jmb.2025.169401_b0570","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.drudis.2006.07.005","article-title":"Exploiting the enhanced permeability and retention effect for tumor targeting","volume":"11","author":"Iyer","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jmb.2025.169401_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2022.102915","article-title":"Enhanced permeability and retention effect: a key facilitator for solid tumor targeting by nanoparticles","volume":"39","author":"Shinde","year":"2022","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"10.1016\/j.jmb.2025.169401_b0580","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S1470-2045(13)70429-7","article-title":"Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study","volume":"14","author":"Awada","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0585","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/JCO.2012.45.1278","article-title":"Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant\/refractory epithelial ovarian cancer","volume":"31","author":"Vergote","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0590","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/S1470-2045(15)00332-0","article-title":"Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Perez","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0595","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cllc.2017.10.007","article-title":"Etirinotecan pegol (NKTR-102) in third-line treatment of patients with metastatic or recurrent non-small-cell lung cancer: results of a phase II study","volume":"19","author":"Aggarwal","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0600","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00280-017-3438-y","article-title":"Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer","volume":"80","author":"Lenz","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jmb.2025.169401_b0605","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2017.08.026","article-title":"A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer","volume":"147","author":"Rustin","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0610","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2022.0514","article-title":"Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial","volume":"8","author":"Tripathy","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0615","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11060-015-1795-0","article-title":"Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma","volume":"123","author":"Nagpal","year":"2015","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.jmb.2025.169401_b0620","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0625","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1021\/jm401644v","article-title":"Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation","volume":"57","author":"Santi","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0630","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1073\/pnas.1215498110","article-title":"Hydrogel drug delivery system with predictable and tunable drug release and degradation rates","volume":"110","author":"Ashley","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169401_b0635","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-019-03987-z","article-title":"PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity","volume":"85","author":"Fontaine","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jmb.2025.169401_b0640","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00280-019-03903-5","article-title":"Species-specific optimization of PEG\u223cSN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft","volume":"84","author":"Fontaine","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jmb.2025.169401_b0645","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00280-019-04017-8","article-title":"Prospective use of the single-mouse experimental design for the evaluation of PLX038A","volume":"85","author":"Ghilu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jmb.2025.169401_b0650","doi-asserted-by":"crossref","first-page":"14175","DOI":"10.1038\/s41598-024-64186-2","article-title":"PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice","volume":"14","author":"Jung","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169401_b0655","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/(SICI)1097-0215(19970807)72:4<680::AID-IJC21>3.0.CO;2-E","article-title":"DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant","volume":"72","author":"Joto","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0660","doi-asserted-by":"crossref","first-page":"E2811","DOI":"10.1073\/pnas.1715350115","article-title":"Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors","volume":"115","author":"Wyatt","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169401_b0665","article-title":"Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity","volume":"3","author":"Gayle","year":"2021","journal-title":"NAR Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0670","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-21-1000","article-title":"TOP1-DNA trapping by exatecan and combination therapy with ATR inhibitor","volume":"21","author":"Jo","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jmb.2025.169401_b0675","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2217\/imt-2022-0121","article-title":"Antigen-independent tumor targeting by CBX-12 (alphalex(\u00a0)-exatecan) induces long-term antitumor immunity","volume":"14","author":"Gayle","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jmb.2025.169401_b0680","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.annonc.2024.08.735","article-title":"669P CBX-12-101: final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors","volume":"35","author":"Lorusso","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jmb.2025.169401_b0685","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/AAC.2.5.395","article-title":"Antiviral action of camptothecin","volume":"2","author":"Horwitz","year":"1972","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2025.169401_b0690","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/248226a0","article-title":"Effect of camptothecin on simian virus 40 DNA","volume":"248","author":"Rubinstein","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169401_b0695","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0042-6822(75)90409-2","article-title":"Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication","volume":"67","author":"Minor","year":"1975","journal-title":"Virology"},{"key":"10.1016\/j.jmb.2025.169401_b0700","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad7993","article-title":"Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation","volume":"352","author":"Rialdi","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169401_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118130","article-title":"Liver injury in septic mice were suppressed by a camptothecin-bile acid conjugate via inhibiting NF-kappaB signaling pathway","volume":"257","author":"Xiao","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.jmb.2025.169401_b0710","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.cell.2021.03.051","article-title":"TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation","volume":"184","author":"Ho","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0715","doi-asserted-by":"crossref","first-page":"8613","DOI":"10.1021\/acs.jmedchem.8b00498","article-title":"Structure-based drug design and identification of H(2)O-soluble and low toxic hexacyclic camptothecin derivatives with improved efficacy in cancer and lethal inflammation models in vivo","volume":"61","author":"Pan","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0720","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31083\/j.fbl2703093","article-title":"A yeast-based screening system for differential identification of poisons and suppressors of human topoisomerase I","volume":"27","author":"Seddek","year":"2022","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.jmb.2025.169401_b0725","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2421167122","article-title":"Patulin and xestoquinol are inhibitors of DNA topoisomerase 1","volume":"122","author":"Tumini","year":"2025","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169401_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107412","article-title":"Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies","volume":"147","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jmb.2025.169401_b0735","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0092-8674(88)90027-X","article-title":"Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerases I and II","volume":"55","author":"Christman","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0740","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1073\/pnas.85.20.7501","article-title":"DNA topoisomerase-targeting antitumor drugs can be studied in yeast","volume":"85","author":"Nitiss","year":"1988","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169401_b0745","first-page":"481","article-title":"Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content","volume":"4","author":"Woessner","year":"1992","journal-title":"Oncol. Res."},{"key":"10.1016\/j.jmb.2025.169401_b0750","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/0008-5472.CAN-20-1741","article-title":"A very long-acting PARP inhibitor suppresses cancer cell growth in DNA repair-deficient tumor models","volume":"81","author":"Fontaine","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0755","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmb.2025.169401_b0760","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.18632\/oncotarget.6497","article-title":"Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmb.2025.169401_b0765","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28772","article-title":"In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-a report from the pediatric preclinical testing consortium","volume":"68","author":"Kurmasheva","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0770","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-23-3383","article-title":"A phase I\/II study of valemetostat (DS-3201b), an EZH1\/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer","volume":"30","author":"Choudhury","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169401_b0775","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/ijc.30256","article-title":"OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models","volume":"139","author":"Berenguer-Daize","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169401_b0780","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s10637-020-01014-0","article-title":"The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway","volume":"39","author":"Lei","year":"2021","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jmb.2025.169401_b0785","doi-asserted-by":"crossref","first-page":"971","DOI":"10.21873\/anticanres.16892","article-title":"BRD4-targeting PROTACs synergize with chemotherapeutics against osteosarcoma cell lines","volume":"44","author":"Lang","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jmb.2025.169401_b0790","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002228362500467X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002228362500467X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:58:31Z","timestamp":1782028711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002228362500467X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":158,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S002228362500467X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2025.169401","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and Future","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2025.169401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"169401"}}